Kowa Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1981-01-01

Employees: 1

Market Cap: -

Website: http://www.kowaus.com

Clinical Trials

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: K-877-ER (Dose B)
Drug: K-877-IR
Drug: K-877-ER (Dose A)

First Posted Date: 2020-06-25

Last Posted Date: 2023-12-22

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 96

Registration Number: NCT04447820

Locations: 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Aventiv Research, Inc., Columbus, Ohio, United States

and more 9 locations

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

Phase 2

Completed

Conditions: Fuchs' Endothelial Corneal Dystrophy

Interventions: Drug: K-321 Solution
Drug: Placebo Solution

First Posted Date: 2020-01-31

Last Posted Date: 2024-11-05

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 65

Registration Number: NCT04250207

Locations: 🇺🇸
Gorovoy MD Eye Specialists, Fort Myers, Florida, United States
🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
🇺🇸
Jules Stein Eye Institute, Los Angeles, California, United States

and more 26 locations

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K-877
Drug: CSG452

First Posted Date: 2020-01-23

Last Posted Date: 2020-09-22

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 20

Registration Number: NCT04237597

Locations: 🇺🇸
PPD Development. LP, Austin, Texas, United States

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye Disease

Interventions: Drug: K-161
Other: Placebo (Vehicle)

First Posted Date: 2019-09-10

Last Posted Date: 2023-03-15

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 238

Registration Number: NCT04084483

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Total Eye Care, P.A., Memphis, Tennessee, United States
🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

and more 1 locations

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K-285
Drug: Indomethacin

First Posted Date: 2018-10-19

Last Posted Date: 2019-01-17

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 15

Registration Number: NCT03712241

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K-877 CR Tablet A
Drug: K-877 CR Tablet B
Drug: K-877 CR Tablet E
Drug: K-877 IR Tablet

First Posted Date: 2018-10-11

Last Posted Date: 2018-12-19

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 12

Registration Number: NCT03702673

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

Not Applicable

Completed

Conditions: Healthy
Retinal Disease
Glaucoma

Interventions: Device: KOWA OCT Bi-µ
Device: Optovue iVue 100

First Posted Date: 2018-04-23

Last Posted Date: 2018-09-10

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 12

Registration Number: NCT03505567

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Phase 3

Terminated

Conditions: Type2 Diabetes
Dyslipidemia

Interventions: Drug: Placebo
Drug: K-877

First Posted Date: 2017-03-07

Last Posted Date: 2023-07-13

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 10544

Registration Number: NCT03071692

Locations: 🇺🇸
Alta Pharmaceutical Research Center, Inc., Dunwoody, Georgia, United States
🇨🇦
Discovery Clinical Services Ltd., Victoria, British Columbia, Canada
🇮🇳
Shree Multispecialty Hospital, Pune, Maharashtra, India

and more 860 locations

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Phase 3

Completed

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: K-877
Drug: Placebo (for K-877)
Drug: Fenofibrate

First Posted Date: 2017-01-05

Last Posted Date: 2022-10-28

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 471

Registration Number: NCT03011450

Locations: 🇺🇸
South Florida Research Solutions LLC., Pembroke Pines, Florida, United States
🇺🇸
Boyett Health Services Inc, Hamilton, Alabama, United States
🇺🇸
Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States

and more 233 locations

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Phase 3

Completed

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: K-877
Drug: Fenofibrate
Drug: Placebo (for K-877)
Drug: Placebo (for Fenofibrate)

First Posted Date: 2016-12-23

Last Posted Date: 2022-11-30

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 551

Registration Number: NCT03001817

Locations: 🇺🇸
Maryland Cardiovascular Specialist, Baltimore, Maryland, United States
🇺🇸
Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States
🇺🇸
Centex Studies, Inc., Houston, Texas, United States

and more 217 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy